Enhancement of perfusion reserve by cardiac resynchronization therapy
With great interest, we read the recent work by Lindner et al., 1 which investigated the effects of cardiac resynchronization therapy (CRT) on regional resting myocardial oxidative metabolism and perfusion. Even though the observed homogenizing effects of CRT on regional metabolism are not new and confirmatory of previously reports, 2, 3 the studied patient population is by far the largest to date. Owing to the large sample size, subgroup analysis was feasible, which hinted at a more favourable effect of CRT in non-ischaemic patients than in ischaemic patients.
Among others, the authors conclude that '. . . studies have to clarify whether longterm CRT is able to improve perfusion and metabolism on a global level suggesting regression of cardiomyopathy'. We would like to point out that our group has recently addressed this issue by demonstrating a (reversible) enhancement of global perfusion reserve during CRT. 3 In line with the results of Lindner et al.,
1 ischaemic heart failure patients tended to improve to a lesser extent than non-ischaemic patients, although the sample size in our study was too small to be able to perform a reliable subgroup analysis. Furthermore, the level of augmentation seemed to be related to the degree of reduction in wall stress, which in turn was related to the degree of reverse remodelling.
Impairment of perfusion reserve is a hallmark of both ischaemic and non-ischaemic cardiomyopathy and an independent prognostic marker for an unfavourable outcome. 4 Regardless of its aetiology, impairment of perfusion reserve is believed to cause repetitive stunning (intermittent periods of ischaemia), leading to chronic reversible left ventricular dysfunction. 4, 5 In fact, signs of ischaemia have been observed in patients with idiopathic dilated cardiomyopathy, making the term 'non-ischaemic' cardiomyopathy a matter of debate. 5 Although the benefit of biventricular pacing is related to mechanical resynchronization of the interventricular septum and lateral free wall, it is likely that enhancement of perfusion reserve and its subsequent reduction of ischaemic episodes also play a role in the recovery of function associated with CRT. In our opinion, this demonstrates, at least in part, a true regression of cardiomyopathy. 
Frans C. Visser

Enhancement of perfusion reserve by cardiac resynchronization therapy: reply
The letter from Dr Knaapen and co-workers raised an interesting and critical point about our conclusion that further studies have to clarify whether long-term cardiac resynchronization therapy (CRT) is able to improve myocardial perfusion and metabolism at a global level, suggesting a regression of cardiomyopathy. This conclusion was based on the observation that global resting MBF and MVO 2 , which were reduced in our cardiomyopathy patients, did not change after 4 months of CRT. 1 As recently demonstrated, there is evidence that CRT is able to improve hyperaemic MBF (1.91 + 1.03 at baseline vs. 2.66 + 1.66 after 3 months of CRT vs. 1.92 + 1.06 mL/min/g during CRT off), which may play a role in functional recovery by CRT due to a reduction in ischaemic episodes. 2 However, this observation was not confirmed by the study of Sundell et al., 3 who reported no significant change in vasodilator MBF (1.8 + 1.1 during CRT on vs. 1.6 + 0.9 mL/ min/g during CRT off) after 8 + 5 months of CRT.
The point of discussion now is to define which criteria need to be applied before one can talk about a real regression of cardiomyopathy. It is beyond doubt that the benefit of CRT is related to an electromechanical resynchronization of the left ventricle, which induces, among other things, a reverse remodelling process and potential improvements in hyperaemic MBF. But as Knaapen et al.
2 also demonstrated, the effect on hyperaemic MBF vanishes as soon as CRT is interrupted. Therefore, we regard it as justified to state that the underlying cardiomyopathic process is not essentially suspended by CRT within a 3-4-month observation period. Nevertheless, the results of Knaapen et al.
2 indicate that CRT initiates mechanisms which could induce a real regression of cardiomyopathy over a long-term period.
Within this context, there is, in our opinion, a basic need to clarify the range of quantitative MBF and MVO 2 in advanced cardiomyopathy. As the current scientific literature indicates, there exists a wide range of data, based to some extent on different methodological approaches, to measure MBF and MVO 2 .
